**Please note errata that affects all books demarcated by dual astricks**
The great thing about obesity medicine is the new advances in treatment options! However, this can make books outdated before the next edition. Therefore, I have added updates and the questions affected below.
NOTE: If you purchased the second edition book from this site or Amazon after 8/2/2022, these updates have already been made in the books themselves, except for those demarcated by **, which applies to all books.
Update topics, followed by questions affected
Inaccurate conversions: The weight in kg for the patient should be 117 kg (NOT 136) and the height should be 178 cm (NOT 170). The chart itself is accurate, and per the lead-in, is recommended to be used to obtain correct answer with given height in inches (70 inches = 5'10") and weight in pounds.
This medication is now approved for those aged 12 and older (previously only approved for adults).
Setmelanotide gained a new FDA indication to treat those with Bardet-Biedl Syndrome.
The term hyperinsulinemic hypoglycmia was changed to post-gastric bypass hypoglycemia (PGBH) to be more consistent with current terminology. A note on late dumping syndrome was also added to the explanation, "Late dumping syndrome may present similarly in timeframe to PGBH but would not cause neuroglycopenia and would respond to dietary changes alone." See new table.
Although listed as a potential concern on the drug insert, meta-analysis has shown no increased risk of pancreatitis or pancreatic cancer with GLP-1 use.
Tirzepatide (Mounjaro®) was recently approved for diabetes and is expected to be soon approved for obesity. The original version stated it was expected to be approved for diabetes soon- well, we made it!
-Triple G (GLP-1, glucagon, and gastric inhibitory peptide) was added to the list of medications actively being studied for weight loss.
Same update description above, followed by questions affected
A company produces a synthetic high-potency hormone that suppresses glucagon production and INCREASES satiety
Exogenous leptin is injected into a test subject. This hormone is found to STIMULATE which of the following pathways?
Note: The answer for 222 has been modified. See updated version.
Add a footnote if this applies to your business
Obesity Medicine Board Review Questions
Copyright © 2023 Obesity Medicine Board Review Questions - All Rights Reserved.
Powered by GoDaddy
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.